Drug Profile
ATL 101 - Alizyme
Alternative Names: ATL101 - Alizyme; AZM 128Latest Information Update: 19 Oct 2001
Price :
$50
*
At a glance
- Originator Alizyme; Rowett Research Institute
- Class Growth factors
- Mechanism of Action Intercellular signalling peptide and protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Mucositis
Most Recent Events
- 19 Oct 2001 Discontinued-Preclinical for Mucositis in United Kingdom (Unknown route)
- 03 Apr 2000 Alizyme has been granted exclusive rights to manufacturing technology for ALT 101
- 30 Oct 1998 Alizyme is discussing out-licensing with potential partners